New Clinical Study Results Indicate Higher Early Virologic Response
with Celgosivir Combination Therapy in HCV Non-Responders
Data to be Presented April 15th at EASL Conference in Barcelona,
VANCOUVER and SAN DIEGO, CA, April 11, 2007
/PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer
of drugs for infectious diseases, has received new top-line results
confirming the previously announced clinical res...
Migenix to Present Celgosivir Phase II Hepatitis C Results at
Digestive Disease Week 2007
VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ -
MIGENIX Inc. , a clinical-stage developer of drugs for infectious
diseases will make a presentation of results from a recent
hepatitis C Phase II combination therapy study (see April 11, 2007
press release) in a non-responder patient p...
Schering-Plough Announces Hepatitis C Data Presentations at
Digestive Disease Week (DDW) 2007 Annual Meeting
Peginterferon Alfa-2b in Treatment-Naive Patients With Chronic HCV;
E.S. Maller, Monday, May 21, 2:15 p.m., Room 206
Phase II Study of celgosivir
in combination with Peginterferon
alfa-2b and ribavirin in chronic hepatitis C genotype 1
nonresponder patients; K.D. Kaita, Monday, May 21, 2:45 p.m....
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
VANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc.
(TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious
diseases, will add a 600mg celgosivir
combination therapy arm to its
currently enrolling Phase II viral kinetics study in hepatitis C virus
MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc.
(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious
diseases will present results of viral resistance studies with its anti-HCV
at the 14th International Symposium on Hepatitis C Vir...
MIGENIX Reports First Quarter Fiscal 2009 Financial Results
...cal study program (previously Cutanea was targeting the end of 2008). celgosivir
(MX-3253; oral alpha-glucosidase I inhibitor; treatment of
chronic hepatiti...e are continuing to seek strategic
options for advancing the development of celgosivir
and are currently in
key partnering discussions.
MX-2401 (IV lipopeptide;...
MIGENIX Corporate Update and Requisition of Special Meeting
...ayments and a single-digit royalty on net
(oral alpha-glucosidase inhibitor for Hepatitis C ...rus
infections): A Phase II study assessing 400 mg celgosivir
pharmacokinetics and viral kinet...pment by the end of
2008; to have results from the celgosivir
Phase II viral kinetics study in
the next several ...
Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
...nt payment(s), milestones and royalty terms
(hepatitis C virus): ----------------------------... - Program-related: The planned extension of the celgosivir
viral kinetics study to include a 600 mg celgosivir
combination arm (600 mg ...
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
...such a partnership(s) is uncertain at this time.
(MX-3253; oral alpha-glucosidase I inhibitor; trea...y is currently
enrolling patients to assess 600 mg celgosivir
pharmacokinetics and viral kinet... to the
standard of care drugs alone and to 400 mg celgosivir
plus the standard of
care for up to 12 weeks of th...
MIGENIX releases CEO message #22
...n H2/08 - NDA submission in H1/09 - Rest of world partnership
(hepatitis C virus): - Phase II viral kinetics study results (includi... application (NDA) being submitted for OmigardTM in the first half of
Phase II viral kinetic results in the third quarter 2008;
CLS001 entering i...
MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
omiganan 1% gel in the first half of 2009.
(MX-3253; oral alpha-glucosidase I inhibitor; trea...ncept and
evidence of clinical benefit when adding celgosivir
to the current
standard-of-care HCV therapy (pegyl...
(SVR). The safety profile for patients exposed to celgosivir
for up to 48
weeks did not differ from those in th...
MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
... Company to Report Interim celgosivir
4-Week Viral Kinetics Study Data on Monday December ...ort interim 4-week data from a Phase
II viral kinetics combination study of celgosivir
in patients with chronic
HCV (genotype 1) infection on Monday December 3, 2...
MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
... Company Provides Revised Timing on Interim celgosivir
Viral Kinetics Study ... prevention of catheter-related infections - celgosivir
- a Phase II product candidate for treating chroni...rom a Phase II
viral kinetics combination study of celgosivir
in patients with chronic HCV
(genotype 1) infectio...